NovoCure Ltd NVCR

NAS: NVCR | ISIN: JE00BYSS4X48   21:09
24,18 USD (+9,96%)
(+9,96%)   21:09
Grafiek NovoCure Ltd Grafiek NovoCure Ltd

NovoCure Ltd in het nieuws

7 augustus 2023 · NVCR Investors Have Opportunity to Lead NovoCure Limited Securities Fraud Lawsuit · Persbericht

5 augustus 2023 · NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR · Persbericht

22 juli 2023 · NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR · Persbericht

14 juli 2023 · Moore Kuehn Announces Encourages Novocure Limited Investors To Contact Law Firm · Persbericht

8 juli 2023 · NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR · Persbericht

24 juni 2023 · NVCR INVESTOR DEADLINE: NovoCure Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit · Persbericht

24 juni 2023 · NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR · Persbericht

21 juni 2023 · Calling all investors in NovoCure Limited (NVCR): New lawsuit lead plaintiff deadline is August 18, 2023 - contact Bronstein, Gewirtz & Grossman, LLC today · Persbericht

Profiel NovoCure Ltd

Gezondheidstechnologie
Medische Specialiteiten
Productie
Productie van medische instrumenten

CEO: Asaf Danziger

Werknemers: 1.224

Aandelen NovoCure Ltd

Beurswaarde: 2,37 miljard USD

Effecten: 107,61 miljoen

Winst per aandeel (12 maand):  PLUS

Beta: 1,90

Mijn selecties